Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
08
2019
revised:
13
11
2019
accepted:
21
11
2019
entrez:
31
12
2019
pubmed:
31
12
2019
medline:
31
12
2019
Statut:
epublish
Résumé
The estimated incidence rate of prostate cancer in Africa was 22.0/100,000 in 2016. The International Agency for Research on Cancer (IARC) has cited prostate cancer as a growing health threat in Africa with approximated 28,006 deaths in 2010 and estimated 57,048 deaths in 2030. The exact incidence of advanced and metastatic prostate cancer is not known in sub-Saharan Africa. Hospital-based reports from the region have shown a rising trend with most patients presenting with advanced or metastatic disease. The management of advanced and metastatic prostate cancer is challenging. The available international guidelines may not be cost-effective for an African population. The most efficient approach in the region has been surgical castration by bilateral orchidectomy or pulpectomy. Medical androgen deprivation therapy is expensive and may not be available. Patients with metastatic castrate-resistant prostate cancer tend to be palliated due to the absence or cost of chemotherapy or second-line androgen deprivation therapy in most of Africa. A cost-effective guideline for developing nations to address the rising burden of advanced prostate cancer is warranted at this moment.
Identifiants
pubmed: 31885569
doi: 10.1155/2019/1785428
pmc: PMC6915139
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1785428Informations de copyright
Copyright © 2019 Ayun Cassell et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest regarding this article.
Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
pubmed: 12359855
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Natl Cancer Inst. 2005 Jun 1;97(11):798-804
pubmed: 15928300
Ann Intern Med. 2006 Mar 21;144(6):441-3
pubmed: 16549857
J Natl Med Assoc. 2002 Jul;94(7):619-27
pubmed: 12126288
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Infect Agent Cancer. 2011 Sep 23;6 Suppl 2:S6
pubmed: 21992406
Eur Urol. 2015 Jun;67(6):1028-1038
pubmed: 25301760
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Pan Afr Med J. 2013 Aug 10;15:129
pubmed: 24255735
Urology. 2010 Aug;76(2):412-6
pubmed: 20451979
Biomed Res Int. 2014;2014:827265
pubmed: 24757679
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
PLoS One. 2016 Apr 13;11(4):e0153496
pubmed: 27073921
Ann Acad Med Singapore. 2015 Oct;44(10):397-405
pubmed: 26763057
Eur Urol. 2000 Oct;38(4):372-9
pubmed: 11025373
BJU Int. 2019 Sep;124(3):373-382
pubmed: 31077523
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
J West Afr Coll Surg. 2016 Oct-Dec;6(4):31-65
pubmed: 29181364
BJU Int. 2005 Apr;95(6):751-6
pubmed: 15794776
J West Afr Coll Surg. 2014 Oct-Dec;4(4):70-81
pubmed: 27182511
J Clin Oncol. 2008 Aug 10;26(23):3879-85
pubmed: 18688056
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Eur Urol. 2015 Feb;67(2):319-25
pubmed: 24684960
World J Oncol. 2019 Oct;10(4-5):162-168
pubmed: 31636789
Eur Urol. 2019 Dec;76(6):790-813
pubmed: 31587989
Prog Urol. 2014 Apr;24(5):271-5
pubmed: 24674331
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
J Urol. 2006 Aug;176(2):564-8
pubmed: 16813890
Ann Oncol. 2008 Mar;19(3):420-32
pubmed: 17906299
East Afr Med J. 2007 Sep;84(9 Suppl):S31-5
pubmed: 18154200
J Glob Oncol. 2015 Sep 23;1(1):30-36
pubmed: 28804769
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
J Urol. 1995 Oct;154(4):1447-52
pubmed: 7658555
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Res Rep Urol. 2019 May 07;11:137-142
pubmed: 31192170
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607